



The Scottish opportunity – harnessing the Scottish population /MS register to deliver new knowledge and improved care

Improved Care & New Knowledge



Multiple Sclerosis

Pathfinder disease in Neurology for Discovery and Therapeutics

And yet despite two decades of increasing
DMT options

We do not understand pathobiology


Or

Have tools to predict disease course

Or

Treatments for disease progression

MS Society Edinburgh Centre for Translational Research



**Edinburgh Centre for
Translational Research**



Adding value and extending links with other MS programmes





MS SMART
Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial

MS-SMART is a £3M UCL/Edinburgh partnership multi-arm phase IIb randomised, double blind placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. It will begin recruiting patients early in 2015.









£2.1M study combining genomic and clinical factors to predict disease activity at the onset of relapsing-remitting MS to improve DMT outcomes and minimise risk.


MS Society Tissue Bank



MS Society Cambridge Centre for Myelin Repair



The Farr Institute of Health Informatics Research




Dementias Platform^{UK}
Medical Research Council

Why stratify in MS?


Subject-specific & widely variable disease activity

Treatment of MS: a risk / benefit tradeoff





Clinical, laboratory & genomic predictors of disease activity in people with newly diagnosed relapsing-onset MS



WHO?

Partnership between four Scottish NHS Boards & Associated Universities [O’Riordan / Overell / Webb / McLeod/ **Connick**]

WHAT?

3-year observational study across Scotland in newly diagnosed RRMS

WHY?

- 1. Can we predict the future at the time of diagnosis?**
- 2. POC for “big data integration”**

**Funding awarded
Summer 2015
Study start Q1 2016?**



1) Develop tools to support prediction at diagnosis

- Allow better care planning
- Allow the possibility of prospective stratification

2) Evaluate the genetic contribution to disease course

3) Further build a lasting Scottish MS Research Consortium

4) Pilot new approaches to data gathering in MS consultations

Recruitment targets

**Begins Q1 2016
for 2-years**


Target n = 515



Grampian

Tayside


Glasgow / WoS

Lothian / SE





THE *FutureMS* HEALTH INFORMATICS FRAMEWORK



Partners



Scottish Enterprise

Highlands & Islands ENTERPRISE

Scottish Funding Council
Promoting further and higher education



Stratified Medicine Scotland
SMS Making a Reality of Stratified Medicine



Innovation Centres
Supported by The Scottish Funding Council, Highlands and Islands Enterprise and Scottish Enterprise.

